FGFR2 and intrahepatic cholangiocarcinoma: This work highlights a major function of oncogenic FGFR2 in metabolic reprogramming of ICC and suggests opportunities to harness the pronounced impairment of glucose utilization resulting from FGFR TKI treatment.